Selected patient characteristics and outcomes according to anti-FVIII IgA titer
| Characteristic . | IgA negative (n = 44) . | IgA ≤ median (≤1:80) (n = 24) . | IgA > median (>1:80) (n = 13) . | P for difference . |
|---|---|---|---|---|
| Gender, n (%) | .0026 | |||
| Female | 22 (50) | 13 (54) | 0 (0) | |
| Male | 22 (50) | 11 (46) | 13 (100) | |
| Underlying disorder, n (%) | .6211 | |||
| None/idiopathic | 25 (57) | 17 (71) | 11 (85) | |
| Autoimmunity | 9 (21) | 4 (17) | 1 (8) | |
| Malignancy | 6 (13) | 2 (8) | 1 (8) | |
| Pregnancy | 4 (9) | 1 (4) | 0 (0) | |
| Age (y), median (IQR) | 74 (61-81) | 76 (71-83) | 74 (61-78) | .8623 |
| Factor VIII activity (IU/dL), median (IQR) | 1.0 (<1-3.7) | <1 (<1-2.4) | 2.0 (<1-3.6) | .8073 |
| Inhibitor concentration (BU/mL), median (IQR) | 19 (7.4-73) | 19 (7.4-67) | 24 (9.4-114) | .8632 |
| Treatment received, n (%) | ||||
| Steroid | 44 (100) | 24 (100) | 13 (100) | — |
| Cyclophosphamide | 15 (34) | 11 (46) | 5 (38) | .6355 |
| Rituximab | 12 (27) | 5 (21) | 6 (46) | .2568 |
| Outcomes, n (%) | ||||
| PR achieved | 41 (93) | 19 (79) | 10 (77) | .1504 |
| CR achieved | 36 (82) | 13 (54) | 3 (23) | .0003 |
| OR achieved | 31 (70) | 13 (54) | 1 (8) | .0003 |
| Early recurrence | 5 (12) | 4 (21) | 5 (50) | .0273 |
| Late recurrence | 7 (19) | 3 (23) | 1 (33) | .8358 |
| Characteristic . | IgA negative (n = 44) . | IgA ≤ median (≤1:80) (n = 24) . | IgA > median (>1:80) (n = 13) . | P for difference . |
|---|---|---|---|---|
| Gender, n (%) | .0026 | |||
| Female | 22 (50) | 13 (54) | 0 (0) | |
| Male | 22 (50) | 11 (46) | 13 (100) | |
| Underlying disorder, n (%) | .6211 | |||
| None/idiopathic | 25 (57) | 17 (71) | 11 (85) | |
| Autoimmunity | 9 (21) | 4 (17) | 1 (8) | |
| Malignancy | 6 (13) | 2 (8) | 1 (8) | |
| Pregnancy | 4 (9) | 1 (4) | 0 (0) | |
| Age (y), median (IQR) | 74 (61-81) | 76 (71-83) | 74 (61-78) | .8623 |
| Factor VIII activity (IU/dL), median (IQR) | 1.0 (<1-3.7) | <1 (<1-2.4) | 2.0 (<1-3.6) | .8073 |
| Inhibitor concentration (BU/mL), median (IQR) | 19 (7.4-73) | 19 (7.4-67) | 24 (9.4-114) | .8632 |
| Treatment received, n (%) | ||||
| Steroid | 44 (100) | 24 (100) | 13 (100) | — |
| Cyclophosphamide | 15 (34) | 11 (46) | 5 (38) | .6355 |
| Rituximab | 12 (27) | 5 (21) | 6 (46) | .2568 |
| Outcomes, n (%) | ||||
| PR achieved | 41 (93) | 19 (79) | 10 (77) | .1504 |
| CR achieved | 36 (82) | 13 (54) | 3 (23) | .0003 |
| OR achieved | 31 (70) | 13 (54) | 1 (8) | .0003 |
| Early recurrence | 5 (12) | 4 (21) | 5 (50) | .0273 |
| Late recurrence | 7 (19) | 3 (23) | 1 (33) | .8358 |
P values indicate statistical significance from χ2 test or Kruskal-Wallis test as appropriate.
IQR, interquartile range.